{
    "clinical_study": {
        "@rank": "13468", 
        "arm_group": [
            {
                "arm_group_label": "BI 691751 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose given over 14 days"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose given over 14 days"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose given over 14 days"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 4", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose given over 14 days"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 5", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose given over 14 days"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 6", 
                "arm_group_type": "Experimental", 
                "description": "multiple dose given over 14 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "It is the objective of this MRD trial to investigate pharmacokinetics, pharmcodynamics,\n      safety and tolerability of rising doses BI 691751 over a treatment period of 14 days to\n      support the further clinical development of this LTA4H-inhibitor. Special emphasis will be\n      given to detect potential effects of BI 691751 on heart rate."
        }, 
        "brief_title": "Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy male subjects according to the investigator\u00b4s assessment, based on a complete\n             medical history including a physical examination, vital signs (BP (blood pressure),\n             PR (pulse rate), 12-lead ECG (electro cardiogramm), and clinical laboratory tests\n\n          -  Age of 18 to 50 years (incl.)\n\n          -  BMI (body mass index) of 18.5 to 29.9 kg/m2 (incl.)\n\n          -  Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP(Good Clinical Practice) and local legislation\n\n          -  Subject is able to understand and communicate in German\n\n        Exclusion criteria:\n\n          -  Any finding in the medical examination (including BP (blood pressure), PR (pulse\n             rate) or ECG (electro cardiogramm) is deviating from normal and judged as clinically\n             relevant by the investigator\n\n          -  Pulse rate outside 45-80 bpm (beats per minutes) or repeated measurement of systolic\n             blood pressure greater than 140 mmHg, diastolic blood pressure greater than 90 mm Hg\n\n          -  Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          -  Any evidence of a concomitant disease judged as clinically relevant by the\n             investigator\n\n          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the trial\n             medication\n\n          -  Diseases of the central nervous system (such as epilepsy), other neurological\n             disorders or psychiatric disorders\n\n          -  History of relevant orthostatic hypotension, fainting spells, or blackouts\n\n          -  Chronic or relevant acute infections\n\n          -  History of relevant allergy or hypersensitivity (including allergy to the trial\n             medication or its excipients)\n\n          -  Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10\n             half-lives of the respective drug prior to administration of trial medication\n\n          -  Within 10 days prior to administration of trial medication, use of drugs that might\n             reasonably influence the results of the trial or that might prolong the QT/QTc\n             interval\n\n          -  Participation in another trial where an investigational drug has been administered\n             within 60 days prior to planned administration of trial medication\n\n          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)\n\n          -  Inability to refrain from smoking during inhouse-confinement\n\n          -  Alcohol abuse (consumption of more 30 g per day for males)\n\n          -  Drug abuse or positive drug screening\n\n          -  Blood donation of  more than 100 mL within 30 days prior to administration of trial\n             medication or intended donation during the trial\n\n          -  Intention to perform excessive physical activities within one week prior to\n             administration of trial medication or during the trial\n\n          -  Inability to comply with dietary regimen of trial site\n\n          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are\n             repeatedly greater than 450 ms in males) or any other relevant ECG finding at\n             screening\n\n          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,\n             hypokalemia, or family history of Long QT Syndrome)\n\n          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,\n             because considered not able to understand and comply with study requirements, or has\n             a condition that would not allow safe participation in the study\n\n          -  Vulnerable subjects, e.g. subjects kept in detention, soldiers, employees of the\n             sponsor or a clinical research organization, involved in this study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148107", 
            "org_study_id": "1334.2", 
            "secondary_id": "2013-003813-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 691751 Dose 1", 
                "description": "BI 691751 Dose 1", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 2", 
                "description": "BI 691751 Dose 2", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 3", 
                "description": "BI 691751 Dose 3", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 4", 
                "description": "BI 691751 Dose 4", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 5", 
                "description": "BI 691751 Dose 5", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 691751 Dose 6", 
                "description": "BI 691751 Dose 6", 
                "intervention_name": "BI 691751", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "1334.2.1 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "7", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "frequency of subjects with drug-related AEs (Adverse event)", 
            "safety_issue": "No", 
            "time_frame": "0 up to 48 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148107"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUCt,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval t after administration of the first dose)", 
                "safety_issue": "No", 
                "time_frame": "0-24 hours"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte inplasma)", 
                "safety_issue": "No", 
                "time_frame": "0-24 hours"
            }, 
            {
                "measure": "AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "312-336 hours"
            }, 
            {
                "measure": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "312-336 hours"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}